French Research Tax Credit Accreditation

21 April 2010

Cyprotex PLC ("Cyprotex" or the Company")

Cyprotex Discovery Receives French Research Tax Credit Accreditation  

Cyprotex (AIM:CRX), the drug discovery technology and information company, is pleased to announce that it has received French research tax credit approval for years 2009 through to 2011.

The French Ministry of Research (Ministère de l'Enseignement Supérieur et de la Recherche) has granted the French R&D tax credit ("Crédit d'Impôt Recherche", CIR) accreditation to Cyprotex as of March 2010. This initiative allows eligible French pharmaceutical, biotech and agricultural companies subject to corporate tax in France, the ability to claim significant tax relief on costs generated in R&D requirements that are outsourced to Cyprotex Discovery.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: 'We are delighted to receive this recognition and approval from the French Ministry of Research which will provide greater opportunities to support our current client base and allow for improved collaborations with future French clients.'

Additional information on the French research tax credit system is available from the Ministère de l'Enseignement Supérieur et de la Recherche site - http://www.enseignementsup-recherche.gouv.fr/

 For further information:

Cyprotex PLC

Dr. Anthony Baxter, Chief Executive Officer

Tel: +44 1625 505 100

[email protected]

www.cyprotex.com

Execution Noble & Company Limited

John Llewellyn-Lloyd

Sam Reynolds

Tel: 020 7456 9191

Public Relations

Financial Dynamics

Ben Brewerton

Ben Atwell

Mo Noonan

Tel: 020 7831 3113